This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Robinson, K. A. Articles by Badylak, S. F. Search for Related Content PubMed PubMed Citation Articles by Robinson, K. A. Articles by Badylak, S. F. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Heart Failure Hazardous Substances DB TEFLON Related Collections Other myocardial biology Other heart failure Animal models of human disease CV surgery: transplantation, ventricular assistance, cardiomyopathy CV surgery: other

(Circulation. 2005;112:I-135 – I-143.)
© 2005 American Heart Association, Inc.

Cell Transplantation and Tissue Engineering

Extracellular Matrix Scaffold for Cardiac Repair

Keith A. Robinson, PhD; Jinshen Li, MD, PhD; Megumi Mathison, MD, PhD; Alka Redkar, PhD; Jianhua Cui, MD; Nicolas A.F. Chronos, MD; Robert G. Matheny, MD; Stephen F. Badylak, DVM, PhD, MD

From the American Cardiovascular Research Institute (K.A.R., J.L., M.M., A.R., J.C., N.A.F.C., R.G.M.), Norcross, Ga; Cardiac Surgical Associates, PC (R.G.M.), Atlanta, Ga; and McGowan Institute of Regenerative Medicine (S.F.B.), Pittsburgh, Pa.

Correspondence to Dr Keith A. Robinson, 3155 Northwoods Place, Norcross, GA 30071. E-mail krobinson{at}acrionline.org

Background— Heart failure remains a significant problem. Tissue-engineered cardiac patches offer potential to treat severe heart failure. We studied an extracellular matrix scaffold for repairing the infarcted left ventricle.

Methods and Results— Pigs (n=42) underwent left ventricular (LV) infarction. At 6 to 8 weeks, either 4-layer multilaminate urinary bladder-derived extracellular matrix or expanded polytetrafluoroethlyene (ePTFE) was implanted as full-thickness LV wall patch replacement. At 1-week, 1-month, or 3-month intervals, pigs were terminated. After macroscopic examination, samples of tissue were prepared for histology, immunocytochemistry, and analysis of cell proportions by flow cytometry. One-week and 1-month patches were intact with thrombus and inflammation; at 1 month, there was also tissue with spindle-shaped cells in proteoglycan-rich and collagenous matrix. More -smooth muscle actin-positive cells were present in urinary bladder matrix (UBM) than in ePTFE (22.2±3.3% versus 8.4±2.7%; P=0.04). At 3 months, UBM was bioresorbed, and a collagen-rich vascularized tissue with numerous myofibroblasts was present. Isolated regions of -sarcomeric actin-positive, intensely -smooth muscle actin-immunopositive, and striated cells were observed. ePTFE at 3 months had foreign-body response with necrosis and calcification. Flow cytometry showed similarities of cells from UBM to normal myocardium, whereas ePTFE had limited cardiomyocyte markers.

Conclusions— Appearance of a fibrocellular tissue that included contractile cells accompanied biodegradation of UBM when implanted as an LV-free wall infarction patch. UBM appears superior to synthetic material for cardiac patching and trends toward myocardial replacement at 3 months.

Key Words: heart failure • surgery • tissue engineering